| HOME >> MEDICINE >> TECHNOLOGY |
Commenting on the collaboration, Dr. Rahul Singhvi, President and CEO of Novavax said, "This collaboration is a critical milestone in addressing one of the most pressing global healthcare issues of the 21st century. We believe the combination of these technologies will enable the creation of a country's rapid response supply and self-sufficiency in pandemic flu vaccine."
GE Healthcare's new ReadyToProcess portfolio of ready-to-use systems and devices is designed to increase speed, simplicity and safety for all areas of bioprocessing, including the time it takes to build and validate a facility. With Novavax's VLP and manufacturing platform, the intention is that it could enable commissioning of a new facility from scratch in approximately two and a half years, half the time for a traditional egg-based vaccine production facility, and at a potential capital reduction of approximately 60 per cent.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services
that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.
GE Healthcare's broad range of products and services enable healthcare
providers to better diagnose and treat cancer, heart disease, neurological
diseases and other conditions earlier. Our vision for the future is to
enable a new "early health" model of care focused on earlier diagnosis,
pre- symptomatic disease detection and disea
'/>"/>
| SOURCE Novavax, Inc. Copyright©2007 PR Newswire. All rights reserved |